Dealstreet

Stryker Acquires Inari Medical: Strategic Expansion into Peripheral Vascular Treatment Market

by

Stryker Completes $3.1 Billion Acquisition of Inari Medical, Entering High-Growth Venous Thrombectomy Market Stryker Corporation (NYSE: SYK), a global leader in medical technology, has completed its acquisition of Inari Medical, Inc. (NASDAQ: NARI), a pioneering developer of devices for venous thromboembolism (VTE) treatment. This strategic $3.1 billion acquisition marks Stryker’s entry into the rapidly growing … Read more

Bain Capital Acquires Mitsubishi Tanabe Pharma

by

Bain Capital, a leading global private investment firm with approximately $160 billion in assets under management, has announced its agreement to acquire Mitsubishi Tanabe Pharma Corporation (MTPC), a renowned Japanese pharmaceutical company with over 300 years of heritage. This transaction represents one of Bain Capital’s largest investments in the pharmaceutical sector and demonstrates its continued … Read more

Pure Health Acquires 60% Stake in Hellenic Health Care Group in $2.3 Billion Deal, Expanding Global Healthcare Reach

by

On Jan. 27, 2025, Pure Health has agreed to acquire a 60% stake in Hellenic Health Care Group (HHG). The transaction values. 2.3 billion at USD. Pure Health is the largest healthcare group in the Middle East. Hellenic Health Care Group is the largest private healthcare provider in Greece and Cyprus. Pure Health Partnering with … Read more

Eli Lilly Shakes Up JPM25 with $2.5B Scorpion Buyout in Breast Cancer Battle

by

Eli Lilly kicked off the 2025 J.P. Morgan Healthcare Conference with a strategic acquisition of Scorpion Therapeutics, securing its PI3Kα pipeline for up to $2.5 billion in upfront payments and milestones. The deal marks a bold move in Lilly’s quest to compete with Novartis and Roche in the lucrative breast cancer market. A Renewed Push … Read more

Johnson & Johnson Steals the Spotlight at JPM Conference with $14.6B Intra-Cellular Therapies Acquisition

by

On Monday, Johnson & Johnson (J&J) made headlines at the J.P. Morgan Healthcare Conference by announcing its agreement to acquire Intra-Cellular Therapies, a pioneering biotech company specializing in treatments for brain diseases. The deal, valued at $132 per share or approximately $14.6 billion, marks the largest biotechnology acquisition since early 2023. A Strategic Play in … Read more